Abstract
Abstract
Background
This paper reports the duration of moderate and severe exacerbations in patients with house dust mite induced allergic asthma and the impact on patients’ quality of life.
Methods
Post-hoc analyses were conducted using data collected during a phase III multi-national trial (MT-04) that investigated time to moderate or severe asthma exacerbation among 485 patients during withdrawal from inhaled corticosteroids. Patient diaries were analysed to ascertain duration of exacerbations. The impact on patients’ quality of life was measured by calculating utilities for five health states using the EuroQol-5 Dimension (EQ-5D-3L) and Asthma Quality of Life Questionnaire (AQL-5D). A regression analysis predicted the disutility of moving from ‘well controlled asthma’ to the other four health states: ‘partially controlled asthma’, ‘uncontrolled asthma’, ‘moderate exacerbation’ and ‘severe exacerbation’.
Results
Two hundred four patients experienced exacerbations. Moderate and severe exacerbations involved statistically significant reductions in lung function compared to the constant peak expiratory flow observed for patients without exacerbations. Lung function decline occurred for 28 days, decreasing approximately 14 days before an exacerbation followed by a return to baseline over 14 days. Asthma symptoms, the use of short-acting β2-agonists, and frequency of nocturnal awakening all increased, starting 10–14 days before an exacerbation, and returned to baseline within 10–28 days following exacerbations. Compared to ‘well controlled asthma’, the disutility of having a ‘moderate exacerbation’ ranged from − 0.0834 to − 0.0921 (EQ-5D-3L) and from − 0.114 to − 0.121 (AQL-5D); and of having a ‘severe exacerbation’ from − 0.115 to − 0.163 (EQ-5D-3L) and from − 0.153 to − 0.217 (AQL-5D), depending on the length of the observation period.
Conclusions
The impact of moderate and severe exacerbations in house dust mite induced allergic asthma extends 14 days before and 28 days after the peak exacerbation event. The impact of exacerbations on patients’ health-related quality of life (HRQoL) continues long after their occurrence.
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference34 articles.
1. Medical Review (2015). Allergens and allergic asthma. Asthma and allergy Foundation of America [cited Feb 05 2018]. Available from: http://www.aafa.org/page/allergic-asthma.aspx.
2. Nathan, R. A. (2007). The burden of allergic rhinitis. Allergy and Asthma Proceedings, 28(1), 3–9.
3. Schatz, M. (2007). A survey of the burden of allergic rhinitis in the USA. Allergy., 62(Suppl 85), 9–16.
4. Sadatsafavi, M., & Fitzgerald, J. M. (2014). Economic burden of asthma [cited Feb 22nd 2018]. Available from: http://www.globalasthmareport.org/burden/economic.php.
5. Ivanova, J. I., Bergman, R., Birnbaum, H. G., Colice, G. L., Silverman, R. A., & McLaurin, K. (2012). Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. The Journal of Allergy and Clinical Immunology, 129(5), 1229–1235.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献